CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 57% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CD19-CD22 CAR-T cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD19-CD22 CAR-T cells overview

Gene therapy is under development as a third line therapy for the treatment of relapsed or refractory B cell lymphoma and relapsed or refractory acute B lymphocytic leukemia. It is administered through intravenous route. The therapy constitutes of genetically manipulated autologous T cells which express chimeric antigen receptor (CAR) targeting cells expressing B lymphocyte antigen CD19 (CD19) and cells expressing B cell receptor CD22 (CD22).

For a complete picture of CD19-CD22 CAR-T cells’s drug-specific PTSR and LoA scores,

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData鈥檚 unrivalled proprietary data will enable you to decode what鈥檚 happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData鈥檚 Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData鈥檚 .